Sotrovimab
Sign in to saveAlso known as VIR-7831, GSK4182136, Xevudy
thumb|140px|A vial of Sotrovimab Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Spike protein of SARS-CoV-2
- Drug.tradename
- Xevudy
- Drug.MedlinePlus
- a621037
- Drug.DailyMedID
- Sotrovimab
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J06
- Drug.ATC_suffix
- BD05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_US_comment
- via emergency use authorization
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Clinical Trials
14 registered- UNKNOWNStudy on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and BahrainAbu Dhabi Health Services Company · NCT05398718
- PHASE1TERMINATEDPharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB StudyFred Hutchinson Cancer Center · NCT05135650
- PHASE2COMPLETEDA Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised IndividualsSophia Koo, M.D. · NCT05210101
- PHASE4TERMINATEDTreatment of Nosocomial COVID-19University of Calgary · NCT04748588
- COMPLETEDCOVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2University of Milano Bicocca · NCT05268601
- PHASE1TERMINATEDRelative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)Vir Biotechnology, Inc. · NCT05280717
Wikidata facts
- Instance of
- monoclonal antibody
Show 1 more fact
- medical condition treated
- COVID-19
Sources (1)
via Wikidata · CC0
~7 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Development and mechanism of action
- Clinical efficacy
- Manufacturing
- Society and culture
- Economics
- Legal status
- Research
- References
- External links
thumb|140px|A vial of Sotrovimab Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.
The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions.
Excerpted from Wikipedia’s “Sotrovimab” article, available under the CC BY-SA 4.0 licence.